[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351901-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351901-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-ezh2-driven-cholesterol-metabolic-vulnerability-through-napabucasin-suppresses-ovarian-cancer-metastasis","Targeting EZH2-driven cholesterol metabolic vulnerability through Napabucasin suppresses ovarian cancer metastasis","","Ovarian cancer remains highly lethal due to late diagnosis, dominant intraperitoneal dissemination, and metastatic implantation that drives peritoneal carcinomatosis and malignant ascites. The study characterizes EZH2 as a PRC2 catalytic subunit implicated in tumor progression and links it to cholesterol metabolism vulnerability regulated via TMED10. Using in vitro and in vivo experiments, EZH2 hyperactivation transcriptionally upregulates SREBP2 and suppresses TMED10 to enhance cholesterol transport. High-throughput screening identifies Napabucasin as an inhibitor of EZH2-driven metabolic rewiring, producing potent anti-tumor effects and translational therapeutic potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-ezh2-driven-cholesterol-metabolic-vulnerability-through-napabucasin-suppresses-ovarian-cancer-metastasis/351901/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-ezh2-driven-cholesterol-metabolic-vulnerability-through-napabucasin-suppresses-ovarian-cancer-metastasis/351901.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is ovarian cancer difficult to manage at curable stages?","Question",{"text":63,"@type":64},"Because ovarian anatomical location and epithelial tumor biology hinder early detection, leading most patients to present with advanced disease and poor survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do EZH2 and TMED10 relate to cholesterol metabolism in this work?",{"text":68,"@type":64},"EZH2 hyperactivation promotes cholesterol metabolism by upregulating SREBP2 and suppressing TMED10, enhancing transmembrane cholesterol transport.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does Napabucasin play in EZH2-driven cholesterol metabolic vulnerability?",{"text":72,"@type":64},"Napabucasin suppresses EZH2-driven cholesterol metabolic rewiring, shows robust anti-tumor activity in EZH2-high ovarian tumors in vivo, and supports translational precision therapy potential.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351901,1790196556,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nTargeting EZH2-driven cholesterol metabolic vulnerability through Napabucasin suppresses ovarian cancer metastasis  \nMingjun Ma 1, Chao Wang 1, Yue Zhang1, Shanshan Cheng1, Jiani Yang 1, Yejun Zou1, Xiu Tian 1, Sijia Gu 1, Jianxiao Li1, Weiwei Cao1, Chao Huang 1, Yaodi Shao1, Yaqian Zhao 1, Yutong Gao 1, Yilin Liu1, Wen Pang 1, Shuo Shi1, Hui Ding1, Minghai Zhang 1, Yifei Cai1, Yongsong Wu1, Renhao Xue 1, Xiawei Cheng 2, Chen Chu 3, Jindan Sheng 1 ✉ and Yu Wang 1 ✉  \n© The Author(s) 2026  \nINTRODUCTION  \nOvarian cancer ranks as the second most lethal gynecologic malignancy globally, with 324,398 new cases and 206,839 deaths recorded in 2022 [1] . The anatomical positioning of the ovaries and the aggressive biology of epithelial carcinomas impede early detection at curable stages [2] . resulting in over 70% of patients presenting with advanced disease at diagnosis. These individuals face poor prognoses (5-year survival: 25–30%), high recurrence rates (>70%), and limited therapeutic options [3] . Primary ovarian tumors metastasize via intraperitoneal dissemination, lymphatic spread, or hematogenous routes, with intraperitoneal dissemination dominating in >90% of advanced cases [4] . This process manifests as peritoneal carcinomatosis and malignant ascites, hallmarks of late-stage disease [5] . Metastatic implants preferentially colonize the omentum and intestinal serosa, driving malignant bowel obstruction—a leading cause of recurrenceassociated mortality [6, 7] . Despite therapeutic advancements, the molecular drivers of ovarian cancer metastasis remain poorly characterized, critically hindering the development of targeted therapies for metastatic progression.  \nEZH2 resides at chromosomal locus 7q35, comprises 20 exons, and encodes a 746-amino-acid protein [8] . As the core catalytic subunit of polycomb repressive complex 2 (PRC2), EZH2  \nmodulates downstream genes and proteins through PRC2-dependent methylation, PRC2-independent methylation, or mechanisms independent of both PRC2 and methylation [9] . It is frequently overexpressed across a spectrum of cancers, where it plays a pivotal role in tumorigenesis, progression, and metastatic dissemination [10] . In ovarian cancer, EZH2 overexpression is observed in approximately 66% of primary epithelial tumors [11] . with its expression levels strongly correlating with advanced disease stage, metastatic potential, and tumor-associated angiogenesis [12, 13] . TMED10, a member of the transmembrane p24 trafﬁcking protein family, localizes to the ER-Golgi intermediate compartment (ERGIC) and is found within COPI-coated vesicles [14] . It functions by oligomerizing to form protein channels that facilitate the transmembrane transport of unconventionally secreted proteins (UPS) into the ERGIC lumen [15] . Dysregulated cholesterol biosynthesis, a hallmark of many cancers, occurs primarily in the endoplasmic reticulum through energy-intensive reactions [16, 17] . Reprogrammed cholesterol metabolism signiﬁcantly contributes to cancer progression by enhancing cellular proliferation, migration, and invasion [16] . Despite these insights, the interplay between EZH2 and TMED10 and their regulatory roles in cholesterol metabolism within ovarian cancer remains poorly understood.  \n1Department of Gynecology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China. 2State Key Laboratory of Bioreactor Engineering, Optogenetics & Synthetic Biology Interdisciplinary Research Center, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai, China. 3Department of Cancer Biology, Dana–Farber Cancer Institute, Boston, MA, USA.  \n✉ ema","cbCaiv2kJEVfaxV6","https://ap.wps.com/l/cbCaiv2kJEVfaxV6","pdf",11395398,23,"English","# Introduction\n# Results\n## EZH2 and TMED10 are highly expressed in ovarian cancer","[{\"question\":\"Why is ovarian cancer difficult to manage at curable stages?\",\"answer\":\"Because ovarian anatomical location and epithelial tumor biology hinder early detection, leading most patients to present with advanced disease and poor survival.\"},{\"question\":\"How do EZH2 and TMED10 relate to cholesterol metabolism in this work?\",\"answer\":\"EZH2 hyperactivation promotes cholesterol metabolism by upregulating SREBP2 and suppressing TMED10, enhancing transmembrane cholesterol transport.\"},{\"question\":\"What role does Napabucasin play in EZH2-driven cholesterol metabolic vulnerability?\",\"answer\":\"Napabucasin suppresses EZH2-driven cholesterol metabolic rewiring, shows robust anti-tumor activity in EZH2-high ovarian tumors in vivo, and supports translational precision therapy potential.\"}]","Targeting EZH2-driven cholesterol metabolic vulnerability through Napabucasin suppresses ovarian cancer metastasis | PDF",1790096467,58,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e257d4bc23bb6f1c73ae6ea4020416c.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed505dd849f28a3f5db9829a2604e077.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acbd8dce13333f70a5f7aa3ee458fc29.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f4446f6222bc20567442b1692ab60b8.webp",980,1301]